The prognostic value of the modified glasgow prognostic score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV)

被引：0

作者：

Chen, L-T. ^{[1
]}

Macarulla, T. M. ^{[2
]}

Belanger, B. ^{[3
]}

Mirakhur, B. ^{[4
]}

de Jong, F. A. ^{[5
]}

Siveke, J. ^{[6
]}

机构：

[1] Natl Inst Canc Res, Natl Hlth Res Inst, Internal Med, Tainan, Taiwan

[2] Vall dHebron Univ Hosp HUVH, Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[3] Ipsen Biopharmaceut Inc, Biometry R&D, Cambridge, MA USA

[4] Ipsen Biopharmaceut Inc, Med Affairs, Basking Ridge, NJ USA

[5] Shire GmbH, Med Affairs, Zug, Switzerland

[6] Univ Hosp Essen, West German Canc Ctr, Div Solid Tumor Translat Oncol, Essen, Germany

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

749P

引用

页数：2